Pegfilgrastim Biosimilars Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change Including: 1) By Application: Chemotherapy Induced Neutropenia; Transplantation; Others 2) By Distribution Channel: Hospital Pharmacies; Retail Pharma

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,000	222 Pages	The Business Research Company	February, 2022	BRC17063777

Best Price Guarantee
Price	from $5,000
Length	222 Pages
Publisher	The Business Research Company
Published Date	February, 2022
SKU	BRC17063777

Pegfilgrastim Biosimilars Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global pegfilgrastim biosimilars market as it emerges from the COVID 19 shut down.

Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:
Where is the largest and fastest growing market for the pegfilgrastim biosimilars? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The pegfilgrastim biosimilars market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider pegfilgrastim biosimilars market; and compares it with other markets.

The report covers the following chapters
Executive Summary – The executive summary section of the report gives a brief overview and summary of the report
Report Structure – This section gives the structure of the report and the information covered in the various sections.
Introduction – The introduction section of the report gives brief introduction about segmentation by geography and segmentation by application and by distribution channel.
Market Characteristics – The market characteristics section of the report defines and explains the pegfilgrastim biosimilars market. This chapter also defines and describes products covered in the report.
Trends And Strategies – This chapter describes the major trends shaping the global pegfilgrastim biosimilars market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
COVID Impact Analysis – This section provides an insight on how the pandemic is impacting the pegfilgrastim biosimilars market.
Global Market Size And Growth – This section contains the global historic (2015-2020) and forecast (2020-2025); and (2025-2030) market values; and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
Regional Analysis – This section contains the historic (2015-2020) and forecast (2020-2025); and (2025-2030) market values and growth and market share comparison by region.
Segmentation – This section contains the market values (2015-2030) and analysis for different segments.
Regional Market Size and Growth – This section contains the region’s market size (2020); historic (2015-2020) and forecast (2020-2025); and (2025-2030) market values; and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific; South America; Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market; background information; government initiatives; regulations; regulatory bodies; associations; corporate tax structure; investments; and major companies.
Competitive Landscape – This section covers details on the competitive landscape of the global pegfilgrastim biosimilars market; estimated market shares and company profiles for the leading players.
Key Mergers And Acquisitions – This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
Market Opportunities And Strategies– This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
Conclusions And Recommendations – This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for pegfilgrastim biosimilars companies in terms of product/service offerings, geographic expansion, price offerings, marketing strategies and target groups.
Appendix – This section includes details on the NAICS codes covered; abbreviations and currencies codes used in this report.

Scope

Markets Covered: 1) By Application: Chemotherapy Induced Neutropenia; Transplantation; Others
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Mail-Order Pharmacies

Companies Mentioned: Coherus BioSciences; Biocon/Mylan; Sandoz (Novartis); Mundipharma GmbH; Dr. Reddy’s Laboratories

Metrics Covered: Number of Enterprises; Number of Employees

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; pegfilgrastim biosimilars indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

1. Pegfilgrastim Biosimilars Market Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction: 6.1. Segmentation By Geography; 6.2. Segmentation By Application; 6.3. Segmentation By Distribution Channel
7. Pegfilgrastim Biosimilars Market Characteristics: 7.1. Market Definition; 7.2. Market Segmentation By Application; 7.2.1. Chemotherapy Induced Neutropenia; 7.2.2. Transplantation; 7.2.3. Others; 7.3. Market Segmentation By Distribution Channel; 7.3.1. Hospital Pharmacies; 7.3.2. Retail Pharmacies; 7.3.3. Mail Order Pharmacies
8. Pegfilgrastim Biosimilars Market Trends And Strategies: 8.1. Revised FDA Regulations To Facilitate Biosimilar Drug Development; 8.2. Robust Research & Development; 8.3. Large Number Of Strategic Partnerships; 8.4. Growing Mergers And Acquisitions; 8.5. Demand For Biosimilars In The Treatment Of Neutropenia
9. Impact Of COVID-19 On Pegfilgrastim Biosimilars Market: 9.1. Impact On Global Pegfilgrastim Biosimilars Market; 9.2. Clinical Trial Delays; 9.3. Impact On Patients; 9.4. Impact On Major Players; 9.5. Future Outlook
10. Global Pegfilgrastim Biosimilars Market Size And Growth: 10.1. Market Size; 10.2. Historic Market Growth, 2015 – 2020, Value ($ Million); 10.2.1. Drivers Of The Market 2015 – 2020; 10.2.2. Restraints On The Market 2015 – 2020; 10.3. Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 10.3.1. Drivers Of The Market 2020 – 2025; 10.3.2. Restraints On The Market 2020 – 2025
11. Global Pegfilgrastim Biosimilars Market Segmentation: 11.1. Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 11.1.1. Chemotherapy Induced Neutropenia; 11.1.2. Transplantation; 11.1.3. Others; 11.2. Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 11.2.1. Hospital Pharmacies; 11.2.2. Retail Pharmacies; 11.2.3. Mail-Order Pharmacies
12. Pegfilgrastim Biosimilars Market, Regional And Country Analysis: 12.1. Global Pegfilgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 12.2. Global Pegfilgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)
13. Asia-Pacific Pegfilgrastim Biosimilars Market: 13.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview; 13.1.1. Region Information; 13.1.2. Market Information; 13.1.3. Background Information; 13.1.4. Government Initiatives; 13.1.5. Regulations; 13.1.6. Regulatory Bodies; 13.1.7. Major Associations; 13.1.8. Taxes Levied; 13.1.9. Corporate Tax Structure; 13.1.10. Investments; 13.1.11. Major Companies; 13.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million); 13.3. Asia-Pacific Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 13.4. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 13.5. Asia-Pacific Pegfilgrastim Biosimilars Market: Country Analysis; 13.6. China Pegfilgrastim Biosimilars Market; 13.7. China Pegfilgrastim Biosimilars Market Overview; 13.7.1. Country Information; 13.7.2. Market Information; 13.7.3. Background Information; 13.7.4. Government Initiatives; 13.7.5. Regulations; 13.7.6. Regulatory Bodies; 13.7.7. Major Associations; 13.7.8. Taxes Levied; 13.7.9. Corporate Tax Structure; 13.7.10. Investments; 13.7.11. Major Companies; 13.8. China Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 13.9. China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 13.10. India Pegfilgrastim Biosimilars Market; 13.11. India Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million); 13.12. India Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 13.13. India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 13.14. Japan Pegfilgrastim Biosimilars Market; 13.15. Japan Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million); 13.16. Japan Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 13.17. Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 13.18. Australia Pegfilgrastim Biosimilars Market; 13.19. Australia Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million); 13.20. Australia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 13.21. Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 13.22. Indonesia Pegfilgrastim Biosimilars Market; 13.23. Indonesia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 13.24. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 13.25. South Korea Pegfilgrastim Biosimilars Market; 13.26. South Korea Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 13.27. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)
14. Western Europe Pegfilgrastim Biosimilars Market: 14.1. Western Europe Pegfilgrastim Biosimilars Market Overview; 14.1.1. Region Information; 14.1.2. Market Information; 14.1.3. Background Information; 14.1.4. Government Initiatives; 14.1.5. Regulations; 14.1.6. Regulatory Bodies; 14.1.7. Major Associations; 14.1.8. Taxes levied; 14.1.9. Corporate Tax Structure; 14.1.10. Investments; 14.1.11. Major Companies; 14.2. Western Europe Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million); 14.3. Western Europe Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 14.4. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 14.5. Western Europe Pegfilgrastim Biosimilars Market: Country Analysis; 14.6. UK Pegfilgrastim Biosimilars Market; 14.7. UK Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million); 14.8. UK Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 14.9. UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 14.10. Germany Pegfilgrastim Biosimilars Market; 14.11. Germany Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million); 14.12. Germany Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 14.13. Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 14.14. France Pegfilgrastim Biosimilars Market; 14.15. France Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million); 14.16. France Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 14.17. France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)
15. Eastern Europe Pegfilgrastim Biosimilars Market: 15.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview; 15.1.1. Region Information; 15.1.2. Market Information; 15.1.3. Background Information; 15.1.4. Government Initiatives; 15.1.5. Regulations; 15.1.6. Regulatory Bodies; 15.1.7. Major Associations; 15.1.8. Taxes levied; 15.1.9. Corporate Tax Structure; 15.1.10. Investments; 15.1.11. Major Companies; 15.2. Eastern Europe Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 15.3. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 15.4. Eastern Europe Pegfilgrastim Biosimilars Market: Country Analysis; 15.5. Russia Pegfilgrastim Biosimilars Market; 15.6. Russia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 15.7. Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)
16. North America Pegfilgrastim Biosimilars Market: 16.1. North America Pegfilgrastim Biosimilars Market Overview; 16.1.1. Region Information; 16.1.2. Market Information; 16.1.3. Background Information; 16.1.4. Government Initiatives; 16.1.5. Regulations; 16.1.6. Regulatory Bodies; 16.1.7. Major Associations; 16.1.8. Taxes Levied; 16.1.9. Corporate Tax Structure; 16.1.10. Investments; 16.1.11. Major Companies; 16.2. North America Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million); 16.3. North America Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 16.4. North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 16.5. North America Pegfilgrastim Biosimilars Market: Country Analysis; 16.6. USA Pegfilgrastim Biosimilars Market; 16.7. USA Pegfilgrastim Biosimilars Market Overview; 16.7.1. Country Information; 16.7.2. Market Information; 16.7.3. Background Information; 16.7.4. Government Initiatives; 16.7.5. Regulations; 16.7.6. Regulatory Bodies; 16.7.7. Major Associations; 16.7.8. Taxes Levied; 16.7.9. Corporate Tax Structure; 16.7.10. Investments; 16.7.11. Major Companies; 16.8. USA Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million); 16.9. USA Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 16.10. USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)
17. South America Pegfilgrastim Biosimilars Market: 17.1. South America Pegfilgrastim Biosimilars Market Overview; 17.1.1. Region Information; 17.1.2. Market Information; 17.1.3. Background Information; 17.1.4. Government Initiatives; 17.1.5. Regulations; 17.1.6. Regulatory Bodies; 17.1.7. Major Associations; 17.1.8. Taxes Levied; 17.1.9. Corporate Tax Structure; 17.1.10. Investments; 17.1.11. Major Companies; 17.2. South America Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 17.3. South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million); 17.4. South America Pegfilgrastim Biosimilars Market: Country Analysis; 17.5. Brazil Pegfilgrastim Biosimilars Market; 17.6. Brazil Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 17.7. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)
18. Middle East Pegfilgrastim Biosimilars Market: 18.1. Middle East Pegfilgrastim Biosimilars Market Overview; 18.1.1. Region Information; 18.1.2. Market Information; 18.1.3. Background Information; 18.1.4. Government Initiatives; 18.1.5. Regulations; 18.1.6. Regulatory Bodies; 18.1.7. Major Associations; 18.1.8. Taxes levied; 18.1.9. Corporate Tax Structure; 18.1.10. Investments; 18.1.11. Major Companies; 18.2. Middle East Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 18.3. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)
19. Africa Pegfilgrastim Biosimilars Market: 19.1. Africa Pegfilgrastim Biosimilars Market Overview; 19.1.1. Region Information; 19.1.2. Market Information; 19.1.3. Background Information; 19.1.4. Government Initiatives; 19.1.5. Regulations; 19.1.6. Regulatory Bodies; 19.1.7. Major Associations; 19.1.8. Taxes Levied; 19.1.9. Corporate Tax Structure; 19.1.10. Investments; 19.1.11. Major Companies; 19.2. Africa Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million); 19.3. Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)
20. Global Pegfilgrastim Biosimilars Market Competitive Landscape: 20.1. Company Profiles; 20.2. Coherus Biosciences Inc.; 20.2.1. Company Overview; 20.2.2. Products And Services; 20.2.3. Business Strategy; 20.2.4. Financial Overview; 20.3. Sandoz (Novartis); 20.3.1. Company Overview; 20.3.2. Products And Services; 20.3.3. Business Strategy; 20.3.4. Financial Overview; 20.4. Biocon; 20.4.1. Company Overview; 20.4.2. Products And Services; 20.4.3. Business Strategy; 20.4.4. Financial Overview; 20.5. Mylan; 20.5.1. Company Overview; 20.5.2. Products And Services; 20.5.3. Business Strategy; 20.5.4. Financial Overview; 20.6. Intas Biopharmaceuticals Ltd; 20.6.1. Company Overview; 20.6.2. Products And Services; 20.6.3. Business Strategy; 20.6.4. Financial Overview; 20.7. Mundipharma GmbH; 20.7.1. Company Overview; 20.7.2. Products And Services; 20.7.3. Business Strategy; 20.7.4. Financial Overview; 20.8. Dr. Reddy’s Laboratories; 20.8.1. Company Overview; 20.8.2. Products And Services; 20.8.3. Business Strategy; 20.8.4. Financial Overview; 20.9. Pfizer Inc.; 20.9.1. Company Overview; 20.9.2. Products And Services; 20.9.3. Business Strategy; 20.9.4. Financial Overview; 20.10. Emcure Pharmaceuticals (Gennova Biopharmaceuticals Ltd.); 20.10.1. Company Overview; 20.10.2. Products And Services; 20.10.3. Financial Overview; 20.11. USV Private Limited; 20.11.1. Company Overview; 20.11.2. Products And Services; 20.11.3. Business Strategy; 20.11.4. Financial Overview
21. Pegfilgrastim Biosimilars Market Pipeline Analysis
22. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market: 22.1. AbCellera Acquired TetraGenetics; 22.2. Ligand Pharmaceuticals Acquired Pfenex; 22.3. True North Acquired Stake In Biocon Biologics; 22.4. Coherus BioSciences Inc Acquired Innovent Biologics Co. Ltd.; 22.5. Biocon Acquires Pfizer's R&D Facility To Boost Biosimilars Development; 22.6. AbbVie Acquired Allergan; 22.7. Kashiv Pharma Acquired Adello Biologics; 22.8. Mundipharma International Limited Acquired Cinfa Biotech; 22.9. Biocon Merged With Sandoz; 22.10. Fresenius Kabi Acquired The Biosimilars Business Of Merck KGaA
23. Pegfilgrastim Biosimilars Market Future Outlook and Potential Analysis: 23.1. Global Pegfilgrastim Biosimilars Market In 2025 – Countries Offering Most New Opportunities; 23.2. Global Pegfilgrastim Biosimilars Market In 2025 – Segments Offering Most New Opportunities; 23.3. Global Pegfilgrastim Biosimilars Market In 2025 – Growth Strategies; 23.3.1. Market Trend Based Strategies; 23.3.2. Competitor Strategies
24. Appendix: 24.1. Market Data Sources; 24.2. Research Methodology; 24.3. Currencies; 24.4. Research Inquiries; 24.5. The Business Research Company; 24.6. Copyright and Disclaimer